Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Central South University
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07356765CT.gov Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms | — | Enrolling By Invitation | — | — | — |
NCT07359209CT.gov Berberine Improving Cognitive Impairments in Schizophrenia | — | Enrolling By Invitation | — | — | — |
NCT05838573CT.gov Metformin Treatment on Cognitive Impairment of Schizophrenia | — | Completed | — | — | — |
NCT05663749CT.gov Topiramate vs Metformin on Cardio-Metabolic Profile in Schizophrenia on Atypical Antipsychotics | — | Completed | — | — | — |
NCT03708549CT.gov Comparison of Berberine and Metformin for the Treatment for MS in Schizophrenia Patients | — | Unknown | — | — | — |
NCT04865835CT.gov A Clinical Trial Study to Determine the Effect of an Investigational Drug (SEP-363856) Has on the Way That the Drug Metformin Travels Through the Body in People With Schizophrenia. | — | Completed | — | — | — |
NCT02983188CT.gov Berberine as Adjuvant Treatment for Schizophrenia Patients | — | Completed | — | — | — |
NCT03451734CT.gov Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients | — | Completed | — | — | — |
NCT02796144CT.gov MEtformin and Lorcaserin for WeighT Loss in Schizophrenia | — | Terminated | — | — | — |
NCT02442817CT.gov Linagliptin and Mesenchymal Stem Cells: A Pilot Study | — | Completed | — | — | — |
Show 7 more trialsShow fewer
NCT03251716CT.gov Berberine Treat Metabolic Syndrome in Schizophrenia | — | Completed | — | — | — |
NCT03548155CT.gov Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia | — | Completed | — | — | — |
NCT02936414CT.gov Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients | — | Completed | — | — | — |
NCT01943019CT.gov Linagliptin in Schizophrenia Patients | — | Terminated | — | — | — |
NCT00802100CT.gov Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia | — | Completed | — | — | — |
NCT00672464CT.gov Cardio Risk of Acute Schizophrenia Olanzapine Duke | — | Withdrawn | — | — | — |
NCT00401973CT.gov Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizophrenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Metformin (this asset) | Central South University | Approved | BB · 70 |
| Trospium | European Group for Research In Schizophrenia | P4 | BBB |
| Xanomeline | European Group for Research In Schizophrenia | P4 | BBB |
| Lurasidone | Aziende Chimiche Riunite Angelini Francesco S.p.A | P4 | BBB |
| Asenapine | Noven Pharmaceuticals, Inc. | P4 | BBB |
| Brexpiprazole | Humanis Saglık Anonim Sirketi | P4 | BBB |
| Bitopertin | Hoffmann-La Roche | P3 | BBB |
| Raloxifene | Shanghai Mental Health Center | P4 | BBB |
| Pyridoxol | Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara | P4 | BBB |
+42 more in the Schizophrenia cohort
Other indications for Metformin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prediabetes Syndrome | — | P4 | A · 81 |
| Gestational Diabetes | — | P4 | A · 81 |
| Diabetes Mellitus | — | P4 | A · 80 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Metformin in Schizophrenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/metformin-schizophrenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →